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ABSTRACT  
   
Severe cases of congenital heart defect (CHD) require surgeries to fix the 
structural problem, in which artificial grafts are often used. Although outcome of 
surgeries has improved over the past decades, there remains to be patients who 
require re-operations due to graft-related complications and the growth of patients 
which results in a mismatch in size between the patient’s anatomy and the implanted 
graft. A graft in which cells of the patient could infiltrate, facilitating transformation 
of the graft to a native-like tissue, and allow the graft to grow with the patient heart 
would be ideal. Cardiac tissue engineering (CTE) technologies, including extracellular 
matrix (ECM)-based hydrogels has emerged as a promising approach for the repair 
of cardiac damage. However, most of the previous studies have mainly focused on 
treatments for ischemic heart disease and related heart failure in adults, therefore 
the potential of CTE for CHD treatment is underexplored. In this study, a hybrid 
hydrogel was developed by combining the ECM derived from cardiac tissue of 
pediatric CHD patients and gelatin methacrylate (GelMA). In addition, the influence 
of incorporating gold nanorods (GNRs) within the hybrid hydrogels was studied. The 
functionalities of the ECM-GelMA-GNR hydrogels as a CTE scaffold were assessed by 
culturing neonatal rat cardiomyocytes on the hydrogel. After 8 days of cell culture, 
highly organized sarcomeric -actinin structures and connexin 43 expression were 
evident in ECM- and GNR-incorporated hydrogels compared to pristine GelMA 
hydrogel, indicating cell maturation and formation of cardiac tissue. The findings of 
this study indicate the promising potential of ECM-GelMA-GNR hybrid hydrogels as a 
CTE approach for CHD treatment.  
As another approach to improve CHD treatment, this study sought the 
possibility of performing a proteomic analysis on cardiac ECM of pediatric CHD 
patient tissue. As the ECM play important roles in regulating cell signaling, there is 
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an increasing interest in studying the ECM proteome and the influences caused by 
diseases. Proteomics on ECM is challenging due to the insoluble nature of ECM 
proteins which makes protein extraction and digestion difficult. In this study, as a 
first step to perform proteomics, optimization on sample preparation procedure was 
attempted. 
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CHAPTER 1 
INTRODUCTION 
1.1 Extracellular matrix 
1.1.1 Overview 
Extracellular matrix (ECM) consists of a complex meshwork of highly cross-
linked proteins and polysaccharides which exists as interstitial forms within the 
tissue and as specialized forms such as basement membranes (Naba et al. 2012). 
According to the report from Naba et al., who characterized the ECM of murine lung 
and colon, the “matrisome” which is defined as the ensemble of ECM proteins and 
associated factors, comprise over 100 ECM proteins (Naba et al. 2012). The mesh-
like structure is formed by core ECM components which involve fibrotic proteins 
(e.g. collagen type I, elastin) and other glycoproteins (e.g. laminin) and 
proteoglycans (Naba et al. 2012). In addition, there is a group of ECM components 
that could be categorized as ECM-affiliated proteins, which refers to proteins that 
share either some architectural or biochemical similarities with the ECM proteins (e. 
g. ficolins, mucins) or that are known to be associated with ECM proteins (Naba et 
al. 2012). Cells interact with the ECM components via transmembrane receptors, 
and this cell-matrix interaction stimulate various signaling pathways that are 
responsible for cell functions including proliferation, survival, and differentiation 
(Naba et al. 2012). The tissue-dependent composition and topology, as well as 
biophysical properties (deformability or stiffness) dictates cell responses (Franz, 
Stewart, and Weaver 2010 and Schwartz 2010). Furthermore, the ECM has a 
heterogeneous, highly dynamic structure that is constantly being remodeled, either 
enzymatically or non-enzymatically, and its molecular components are subjected to 
numerous post-translational modifications (Franz, Stewart, and Weaver 2010). This 
complexity allows the ECM to provide the right cues to the cells. Along with its 
  2 
structural role, ECM is also responsible for the buffering actions that maintain 
homeostasis and water retention of the ECM (Franz, Stewart, and Weaver 2010). 
Moreover, it serves as a reservoir of growth factors, cytokines, and ECM-remodeling 
enzymes which collaborate with ECM proteins and cell-surface receptors to 
modulate cell signaling (Naba et al. 2012).  
The interaction between the ECM and cells is mainly mediated by integrins, a 
transmembrane heterodimer. Integrins serve as a link between the cytoskeleton 
and ECM components (Alberts et al. 2002 and Danen n.d.) allowing cells to convert 
the mechanical signals to biochemical signals (Geiger et al. 2001). This integrin-
mediated interaction modulates signaling cascades which are responsible for 
important cellular processes including cell motility, survival, proliferation, and 
differentiation (Danen n.d.). 
1.1.2 Components of the ECM 
Collagen is known to be the most abundant protein within the ECM (Yue 2014). 
28 types of collagens have been identified in vertebrates (Gordon and Hahn 2010), 
all of which have the basic structure of triple helix (Mouw, Ou, and Weaver 2014). 
Collagen triple helix serves as a motif to which various proteins, including cell surface 
receptors and glycosaminoglycans (GAGs), could bind (Mouw, Ou, and Weaver 
2014). Collagen types I and III is the primary component of cardiac interstitial 
collagen (Villarreal and Kim 1998) and serve as a backbone of ECM. These types 
form fibrils where collagen molecules are packed together in a side-by-side manner 
by formation of covalent cross-links between the lysine residues of two collagen 
chains. This interaction stabilizes the side-by-side structure and contribute to the 
tensile strength of collagen fibers (Lodish et al. 2000).  
Elastin is another fibrotic protein in the ECM, which is the main component of 
elastic fibers. Elastic fibers are a network found in the ECM of tissues which requires 
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strength and elasticity, such as blood vessels. Elastin is a highly hydrophobic protein 
which are formed by intensive crosslinking of tropoelastin into the form of network of 
fibers and sheets. The elastin core is surrounded by a sheath of microfibrils made of 
glycoproteins, such as fibrillin (Alberts et al. 2002).  
Fibronectin are also found as fibrils in the ECM. Formation of fibronectin fibrils 
takes place on the surface of specific cells (e.g. fibroblasts) (Alberts et al. 2002). The 
resulting fibrils are highly insoluble due to disulfide bonds formed between 
fibronectin dimers (Alberts et al. 2002). Fibronectin and intracellular actin filaments 
interact via integrins, which interaction is responsible for assembly of fibrils as well 
as cell adhesion (Alberts et al. 2002). Furthermore, it has been demonstrated that 
fibronectin is an essential component of heart development. Lack of fibronectin 
during development results in abnormalities in blood vessel formation, which is 
thought to be due to alteration in cell-ECM interactions (Alberts et al. 2002). 
Collagen type IV and laminin forms the reticulum of the basal lamina, a sheet-
like structure on which most epithelial and endothelial cells reside on. Both have 
binding sites for a vast range of macromolecules, including proteoglycans and cell 
surface receptors (Lodish et al. 2002). Entactin, a basal lamina protein, facilitates 
the assembly of the basal lamina by linking the laminin and collagen type IV. 
Entactin can also bind to fibronectin (Chung and Durkin 1990).   
In addition to the insoluble components of ECM described above, the ECM 
contains soluble components, such as proteoglycans. Proteoglycans consist of a core 
protein and one or more covalently attached GAGs, which are linear polysaccharides. 
Due to the high content of charged polysaccharides, proteoglycans are highly 
hydrated. This property contributes to the role of ECM to maintain its volume and 
water content, as well as to facilitate diffusion of small molecules between cells and 
tissues (Lodish et al. 2002 and Alberts et al. 2002). In addition, proteoglycans can 
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bind to various bioactive molecules including ECM-affiliated proteins, ECM regulators, 
and secreted factors, and thought to be contributing to regulation of cell activities 
(Alberts et al. 2002). The binding between proteoglycans and bioactive molecules 
can control the range and duration of activity of the bioactive molecules, as the 
molecules can be immobilized to be effective in a specific region, released in a 
controlled manner, and could be protected from proteolytic degradation (Alberts et 
al. 2002). Furthermore, proteoglycans can control the activity of proteins by either 
steric blocking or by alteration of the presentation to cell-surface receptors (Alberts 
et al. 2002). Perlecan is a type of heparan sulfate proteoglycan. By its modular 
structure, it takes part in a wide range of cellular processes including adhesion, 
proliferation, modulation of growth factor signaling, autophagy, cardiovascular 
development, inflammation and wound healing (Gubbiotti, Neill, and Iozzo 2017, 
Jung et al. 2013, Lord et al. 2014, and Zoeller et al. 2008).   
As described above, the ECM involves an intricate and dynamic orchestration of 
a vast range of macromolecules. This complexity allows the interaction between the 
ECM and cells to initiate the right cues for cell signaling and dictates cell activity and 
tissue functions. 
1.2 ECM-inspired tissue engineering approaches 
Recent research has revealed the importance of ECM not only as a structure for 
cells to reside, but also as a regulator of cell signaling, guiding them to function in an 
organized tissue-specific manner. In this regard, the ECM has a high potential as a 
material for tissue engineering.  
Several types of studies have attempted to mimic the structure and functions 
of ECM using synthetic materials. The approaches to reproduce the architecture of 
ECM include utilization of micro- and nanofibrillar synthetic biomaterial (Oberpenning 
et al. 1999), in situ formation of nanofibrillar structures using supramolecular self-
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assembly (Kisiday et al. 2002), and micropatterning (Cio et al. 2017). Mann et al. 
employed a different approach where they attempted to mimic the proteolytic 
recognition of natural ECMs by incorporating proteolytically degradable domains in 
synthetic polymer gels (Mann et al. 2001). This approach is based on the knowledge 
that degradation of ECM components stimulates ECM-cell interaction and cell 
signaling (Lutolf and Hubbell 2005). As another approach to mimic a different aspect 
of ECM, i.e. a reservoir of growth factors, biomaterials with features of controlled 
delivery (Chen and Mooney 2003) or sequential delivery (Zisch et al. 2003) of 
growth factors have been developed. Lastly, techniques to immobilize active ligands 
to a polymer material can also be utilized to create an ECM-like scaffold. (Lutolf and 
Hubbell 2005). This approach has been employed in multiple studies which aimed to 
understand the mechanism of cell-ECM interaction (Irvine et al. 2002 and Brandley 
and Schnaar 1989). The abovementioned approaches succeed in mimicking some 
aspects of the ECM and controlling relatively simple cellular processes. However, 
compared to the intricate and dynamic nature of the natural ECMs, where complex 
temporal and spatial coordination of many different cell-matrix and cell-cell 
interactions take place, they are still oversimplified mimics (Lutolf and Hubbell 
2005). Therefore, further research is awaited to control more complicated cell 
signaling processes simultaneously and sequentially in order to mimic the complexity 
of ECM. 
1.3 Utilization of ECM derived from biological sources 
Given the complexity and incomplete understanding in the nature of the ECM, 
fabrication of an ECM scaffold that fully mimics the biochemistry and architecture of 
natural ECM is currently not possible (Hussey, Dziki, and Badylak 2018). 
Alternatively, an approach to derive ECM from tissues via decellularization can allow 
restoration of tissue-specific microarchitecture and molecular composition (Hussey, 
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Dziki, and Badylak 2018). In addition, the derived ECM can be used in various forms, 
which could be another reason for this approach to be utilized in various studies 
(Figure 1). As mentioned later in detail, the small intestine submucosa ECM (SIS-
ECM) is now used in cardiac surgery including corrective surgery for CHD. Given that 
the ECM has a tissue-specific composition which could affect cell-matrix interactions, 
it would be reasonable to argue that cardiac ECM could potentially be advantageous 
for cardiac tissue regeneration. Zhang and colleagues, in their in vitro study using 
skin, muscle, and liver cells, reported improved cell adhesion, growth rate, and 
phenotype when tissue-specific ECM solutions were used to coat cell culture dishes 
(Zhang et al. 2009).  
Cardiac ECM have been utilized mostly in the form of injectable hydrogels which 
aim to repair cardiac damages caused by ischemic heart diseases. Injectable ECM 
Figure 1 Decellularized tissue materials made from various tissues. After 
removing the cellular contents of the native tissue, the extracellular matrix 
remains and can be left unprocessed as an entire organ, or be processed 
into a section, hydrogel, or coating. The tissues that have been processed 
for the purpose of testing cell differentiation effects are shown below each 
material category. Adapted from (Agmon and Christman 2016) with 
permission from ELSEVIER. 
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hydrogels could be obtained by either enzymatic digestion or homogenization of 
ECM. The hydrogel can be injected solely or as a carrier to deliver cells.  
Extensive study on injectable ECM hydrogels has been carried out by Christman 
laboratory (Johnson et al. 2014 and 2016, Seif-Naraghi et al. 2013, Singelyn et al. 
2009 and 2012, Wassenaar et al. 2016a and 2016b). They have optimized the 
protocol to decellularize porcine and human cardiac tissue, where the tissue is 
decellularized using sodium dodecyl sulfate (SDS) and then digestion using pepsin 
(Johnson et al. 2014 and 2016). The obtained myocardial ECM retained protein 
components including structural proteins and glycosaminoglycans (Johnson et al. 
2014 and Singelyn et al. 2009) and had the ability to self-assemble into a 
nanofibrous structure at 37 °C. Infiltration of endothelial cells and smooth muscle 
cells was observed in in vitro and in vivo studies (Singelyn et al. 2009). Injection of 
porcine-derived ECM hydrogel to rat hearts which underwent ischemia and 
reperfusion, resulted in increased recruitment of endogenous cardiomyocytes in the 
infarcted area (Singelyn et al. 2012). Furthermore, to confirm the safety of the ECM 
hydrogel, they evaluated the biocompatibility of the material using a rat model. In 
the healthy rats which received intramyocardial injections of ECM hydrogels, no signs 
of chronic inflammation were found, which indicate the biocompatible nature of the 
hydrogel. Hemocompatibility study using human blood also gave positive results as 
no effect on clotting times or platelet activation was observed (Seif-Naraghi et al. 
2013). In addition to the above studies, they have carried out studies to understand 
the underlying mechanism of tissue regeneration which occur in the ECM hydrogels 
(Wassenaar et al. 2016b), as well as studies on approaches to modulate the 
mechanical properties of the ECM hydrogel (Wassenaar et al. 2016a and Johnson et 
al. 2011).  
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In line with the results reported by Christman laboratory, Dai et al. reported 
encouraging results on the potential of injectable ECM hydrogels to repair cardiac 
damage caused by myocardial infarction (MI). Cardiac ECM hydrogels were injected 
to the infarcted area 1 week after MI was induced. Assessment carried out at 6 
months after injection revealed higher left ventricular (LV) ejection fraction and 
increased thickness of infarcted LV wall, as well as reduction in extent of LV systolic 
bulging in the ECM-treated group compared to saline-treated group. The findings 
indicate the promising potential of the ECM in cardiac function restoration of the 
infarcted area (Dai et al. 2013).  
1.4 Congenital heart defect 
Congenital heart defect (CHD) refers to structural problems due to abnormal 
formation of the heart or major blood vessels. At least 18 distinct types of CHD are 
known, with many additional anatomic variations (American Heart Association (AHA) 
n.d.). Examples of defects include holes in the septal (e.g. atrial septal defect, 
ventricular septal defect (VSD), atrioventricular septal defect) and aorta (e.g. patent 
ductus arteriosis), abnormalities in vessel connection (e.g. total anomalous 
pulmonary venous connection, transposition of the great arteries), narrowing of 
major arteries (e.g. coarctation of the aorta), problems in valve function (e.g. 
pulmonary valve stenosis, aortic valve stenosis, Ebstein's anomaly, tricuspid atresia, 
pulmonary atresia), and underdevelopment of chambers (e.g. hypoplastic left heart 
syndrome (HLHS)) (AHA n. d.) (Figure 2). Severity can range from simple defects 
that could be treated with non-surgical approaches, to complex structural problems 
such as Tetralogy of Fallot (TOF: a combination of four heart defects) and HLHS, 
where surgical correction is necessary (AHA n.d.). Approximately 1% of new born 
babies are diagnosed as CHD, including 25% of severe CHDs who requires surgical 
interventions (Botto, Correa, and Erickson 2001). Surgeries often use artificial grafts 
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to fix the defect. Thanks to the advance in medicine and surgical techniques, 
outcomes of surgical interventions for CHD have improved dramatically over the past 
decades (Castañeda, 2005). However, there remains patients who require multiple 
re-interventions throughout their lifetime because of graft-related complications 
Figure 2 Congenital heart abnormalities in the new born. Adapted from 
(Nucleus Medical Media 2015) with permission. 
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including degeneration and calcification, and the growth of patients resulting in a 
mismatch in size between the patient’s anatomy and the implanted graft.  (Witt et al. 
2013, and Holst et al. 2018). As repeated operations incur additive risks (Holst et al. 
2018) and causes burden and pain to the patient, minimizing the number of re-
interventions could be an effective approach to improve outcome of CHD treatment.  
Surgical procedures, although they may differ depending on the type of defect 
and the patient’s condition, could involve the following types of procedures to correct 
abnormalities in blood circulation; closure of holes by stitching or using a patch, 
enlargement or bypassing of narrowed vessels, cutting and reconnecting vessels, 
and replacement or repair of heart valves (MedlinePlus n.d.). These surgical 
procedures often require additional substances to “patch” the heart. Autologous 
pericardium can be used, however, the amount of tissue that could be harvested is 
limited. In cases where a large substance is necessary, synthetic materials such as 
Dacron (polyethylene terephthalate) and Gore-tex (polytetrafluoroethylene: PTFE) or 
bovine pericardium are often used (Kimura 2018 and MedlinePlus n.d.). Although the 
outcomes of surgeries using these materials are now good, a common critical 
limitation of these materials is the lack of capacity to grow (Kimura 2018). Growth is 
an important factor that should be considered in CHD treatment, as growth from 
infant to adult involve significant changes in size of the anatomical structures. There 
is an unmet need for a graft which could grow with the patient after implantation 
(Kimura 2018), as it can potentially avoid re-interventions due to size discrepancy 
between the patient’s anatomy and the implanted graft when the patient grows up. 
1.5 Tissue engineering approaches for CHD treatment  
Cardiac tissue engineering (CTE) techniques has the potential to address the 
need of grafts with desirable features including architecture, material composition 
and growth potential. Tissue engineering approaches which have potential for CHD 
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 treatment include; (1) scaffold-based approaches, (2) scaffold-free approaches, (3) 
decellularization-recellularization (Zimmermann and Cesnjevar 2009) (Figure 3), 
and (4) biotubes (Kato et al. 2016).    
Figure 3 Construction strategies in heart tissue engineering. For the 
decellularization-based construction strategy, human or animal donor‐
derived hearts undergo the process of decellularization to obtain 
decellularized whole heart scaffolds with preserved macroarchitecture. 
Regenerative cells (e.g., myocardial cells and endothelial cells) are seeded 
onto decellularized scaffold through perfusion. Repopulated scaffolds are 
placed under 3D culture condition in a bioreactor, yielding tissue‐
engineered whole heart with overall structure and vasculature of heart. 
For the cell sheet-based construction strategy, 3D construct was produced 
by layering 2D myocardial cell sheets, leading to formation of myocardial 
tissue. For the synthetic/natural materials-based construction strategy, 
cells (e.g., myocardial cells), scaffolds (e.g., collagen), and growth factors 
are combined in vitro to produce myocardial tissue.  
Adapted from (Zheng et al. 2018) with permission from John Wiley & 
Sons, Ltd. 
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1.5.1 Scaffold-based tissue engineering approaches 
Many groups who took the scaffold-based approaches have sought to create tissue 
engineering scaffolds using polymer materials. A variety of materials have been 
studied including synthetic materials (e.g. polylactic acid (PLA) and polyglycolic acid 
(PGA) and their copolymers (Ozawa et al. 2002a and 2002b, Shin’oka et al. 2005), 
polyhydroxybutyrate (PHB) (Stock et al. 2000 and Malm et al. 1994), polyester 
urethane (PEUU) (Fujimoto et al. 2007)), as well as materials derived from biological 
sources (e.g. gelatin (Li et al. 1999 and Sakai et al. 2001), alginate (Gaetani et al. 
2012)). These materials could be prepared in porous structures (e.g. sponges, 
meshes) (Zimmermann and Cesnjevar 2009) and could be formed as patches, 
conduits, and valves in order to be used for surgeries. Scaffolds are advantageous as 
it can support cell attachment and provide structural integrity during early stage of 
tissue regeneration, which is important when considering in situ cardiac tissue 
regeneration, as the implanted graft could be exposed to mechanical force under 
physiological conditions (Benrashid et al. 2016). The requirements for an ideal 
scaffold include the following attributes; biocompatible, has adequate mechanical 
strength while being pliable, can be sutured, has low incidence of immunological 
response, infections, calcification, and thrombosis, and has the capability to remodel 
into a functional tissue (Benrashid et al. 2016). Especially in the case of tissue 
engineering for CHD treatment applications, where patient growth is one of the 
important factors to consider, biodegradable/bioabsorbable materials are preferred 
as it is thought that the scaffold would eventually be replaced with a new tissue 
formed by the patient’s own cells, which can grow with the patient. (Ozawa et al. 
2002b). Hoerstrup et al. has demonstrated the potential of growth in a tissue-
engineered vascular graft (TEVG) made by seeding myofibroblasts and endothelial 
cells to a PGA/PHB scaffold. They implanted the TEVG into a growing lamb model and 
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observed significant increase in diameter and length. Furthermore, histology 
indicated native-artery-like tissue formation. Degradation of PGA and PHB were 
confirmed during the 100-week follow up (Hoerstrup et al. 2006).  
      The efficacy of TEVG has been evaluated in clinical trials as well. A group from 
Tokyo Women’s Medical University performed implantation of tissue engineered 
grafts to 42 patients since 2001. The engineered tissue graft was made by combining 
a copolymer of lactide acid and ε -caprolactone with a woven fabric sheet of poly-L-
lactide acid (PLLA) or PGA. Autologous bone marrow cells (BMC) were seeded onto 
the graft prior to implantation. Short-term follow-up (median 16.7 months) reported 
satisfactory results where no graft-related complications occurred and the tube graft 
remained patent. The same group also conducted a long-term follow-up (mean 5.8 
years) for 25 patients and reported that graft stenosis and thrombosis occurred in 4 
and 1 patients, respectively. No aneurysm, graft rupture, infection or ectopic 
calcification were found (Shinoka et al. 2005 and Hibino et al. 2010). It is 
noteworthy that 96% of patients who received TEVG implantation were able to 
discontinue anticoagulation therapy after 6 months from the operation, while 
implantation of synthetic grafts (Dacron and Gore-tex) usually require long-term 
anticoagulation drugs (Hibino et al. 2010). As graft stenosis is one of the known 
complications that could occur in synthetic grafts as well, in other words, not specific 
to TEVG, it could be said that the reported results demonstrated the feasibility of 
tissue-engineered grafts and the potential benefits it may bring to CHD patients 
(Hibino et al. 2010). 
      To date, majority of scaffold-based tissue engineering studies employs cell-
seeded graft approaches. Ozawa et al., who compared biodegradable (gelatin, PGA, 
Poly(ε- caprolactone-co-L-lactide): PCLA) and non-biodegradabe (PTFE) materials by 
implanting unseeded patches to a rat model in a manner that mimics right 
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ventricular outflow tract (RVOT) repair, reported that although host cell infiltration 
was observed in biodegradable patches after 8 weeks of implantation, they were 
predominantly fibroblast and collagen. As localized dilatation of vessels (e.g. 
aneurysms) occur in a similar fashion, considering risks, they suggested that cell-
seeding on tissue engineering scaffolds prior to implantation may be essential 
(Ozawa et al. 2002).  
      Subsequently, several studies have reported interesting findings regarding the 
role of seeded cells. Roh et al. used a mouse model to elucidate the mechanism of 
tissue regeneration which was observed in human BMC-seeded TEVG. They found 
that the human cells seeded on the graft were not detectable from 1 week after the 
implantation. By comparing seeded and unseeded scaffolds, they demonstrated that 
the seeded human BMCs contributed to higher host cell recruitment via a paracrine 
mechanism. In particular, significantly high levels of monocyte chemotactic protein-1 
(MCP-1) secretion were found in human BMC-seeded scaffolds. When MCP-1 
microparticles were embedded in unseeded scaffold, significant improvement in host 
cell recruitment was observed (Roh et al. 2010). Furthermore, Hibino and colleagues 
demonstrated that the neotissue formed on the graft mainly consist of host-derived 
cells. Using a sex-mismatched chimeric mouse model, where the graft was seeded 
with male BMC and implanted to female CB57BL/6 mice, and the source of the cells 
which populated the TEVG was determined by detecting the Y chromosome (Hibino 
et al. 2011). The above findings indicate that cell-seeding to the graft is not 
indispensable. The authors claim that considering the burden which autologous cell 
harvest would cause to the patient and clinical staffs, a cell-free approach could be 
more beneficial (Hibino et al. 2011). Patterson et al. also suggested the advantage of 
cell-free tissue engineering grafts, referring to integration of TEVGs with controlled 
release systems of cytokines as a potential approach (Patterson et al. 2012).  
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      Recently, Matsumura and colleagues have developed a cell-free TEVG and 
demonstrated its potential as in situ tissue engineering scaffold. The TEVG is 
composed of polyglycolide knitted fibers and a PCLA sponge reinforced with glycolide 
and -caprolactone copolymer (P(GA/CL)) monofilament. The TEVGs were implanted 
in a canine inferior vena cava (IVC) model and followed up for 24 months. 
Interestingly, the content of hydroxyproline, elastin, and calcium of the TEVG were 
comparable to that of native IVC. Moreover, histology indicated formation of vessel-
like tissue. The authors attributed this success to the optimal mechanical properties 
and degradation time of the scaffold. In particular, in their previous studies, they 
observed that internal surface endothelialization of the scaffold occurs within a 
month after implantation, and that if fibrotic tissues massively proliferated during 
this initial period, it would lead to stenotic changes of the TEVG. Thus, they 
fabricated the scaffold as it would maintain its shape during the endothelialization 
period, which was achieved by the P(GA/CL) monofilament reinforcement. While the 
P(GA/CL) monofilament degraded within 2 months, the PCLA spongy scaffold 
degraded concurrently but more slowly, to maintain a relatively constant elasticity in 
the TEVG to support the tissue remodeling process. (Mastumura et al. 2012).  
      As discussed earlier, ECM has many advantages as a material for tissue 
engineering applications. SIS-ECM derived from porcine has been recently approved 
by the Food and Drug Administration (FDA) and has been introduced to cardiac 
surgery (Diagnostic and Interventional Cardiology n.d.). SIS-ECM is thought to serve 
as a bioscaffold which allows native cells of the implanted region to grow into the 
scaffold and regenerate native tissue (Kimura 2018). Clinical performance of SIS-
ECM in CHD surgeries appears to be mixed results. Quarti et al. reported that none 
of the 26 patients who received SIS-ECM implantation experienced graft-related 
complications (Quarti et al. 2011). Similarly, Scholl et al. reported overall good 
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outcomes in the 40 patients they performed SIS-ECM implantation. Re-operation was 
required in one patient due to regurgitation of the tricuspid valve which was repaired 
using SIS-ECM. The explanted tissue exhibited signs of resorption of the SIS-ECM, 
replacement with organized collagen, and re-endothelialization which indicates the 
potential of SIS-ECM to be replaced by autologous tissue (Scholl et al. 2010). On the 
other hand, multiple groups have reported unsatisfactory results. Rosario-Quinones 
et al. reported that out of 25 cases where SIS-ECM were used in CHD surgery, 6 
patients required reoperation, all exhibiting hemodynamically significant lesions at 
the site of the SIS-ECM implantation. Signs of intense inflammatory reaction with 
accompanying granulation tissue and fibrosis were observed in histological analysis 
of explanted specimens (Rosario-Quinones et al. 2015). Nelson and colleagues who 
used SIS-ECM patches as a hemi-Fontan baffle during the palliative procedure and 
subsequently explanted them as part of standard Fontan operation observed 
inflammatory responses in all explanted patches. Furthermore, they reported that 
none of the explanted specimens showed evidence of ingrowth of native cells to the 
SIS-ECM or transformation into cardiac tissue (Nelson et al. 2016). Similarly, 
Hofmann and colleagues reported 5 cases of valve insufficiencies out of 6 patients 
who received aortic valve procedures using SIS-ECM. No signs of the expected 
remodeling of SIS-ECM into native-like tissue were found in the explanted specimens 
(Hofmann et al. 2017). Zaidi et al. who examined the explanted SIS-ECM used for 
valve reconstruction in CHD also reported similar results. The authors suggested the 
discrepancy in outcomes could potentially be due to difference in location and 
manner of implantation, such as whether the SIS-ECM was in contact with native 
tissue or blood stream, normal or abnormal tissue (Zaidi et al. 2014). Clinical 
experiences are now accumulating, which may in the future aid identification of 
appropriate patients and indications to use SIS-ECM, and lead to improved outcome.  
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      Along with clinical efforts, research to improve the efficacy of SIS-ECM is in 
progress. Tanaka and colleagues developed a SIS-ECM patch combined with a 
controlled release of basic fibroblast growth factor (bFGF) and compared its 
performance with pristine SIS-ECM and Dacron patches using a porcine model. 
Histological analysis suggested that bFGF-incorporated SIS-ECM enhanced ingrowth 
of host cells and constructive myocardial remodeling. Moreover, cardiac magnetic 
resonance measurement results as well as regional staining observations indicated 
early restoration of contractility and tissue perfusion in the bFGF-incorporated SIS-
ECM compared to control patches (Tanaka et al. 2015). 
      While cardiac ECM have demonstrated promising potential in cardiac tissue 
repair for ischemic heart disease treatment, limited number of studies have reported 
its application for CHD treatment. Wainwright et al. used a cardiac ECM patch 
obtained by performing perfusion decellularization on porcine hearts to repair the 
full-thickness RVOT defect created in a rat model. After 16 weeks, the cardiac ECM 
patch remodeled from an acellular collagen-rich scaffold into a vascularized 
collagenous tissue with scattered small islands of cardiomyocytes. In contrast, 
Dacron patches implanted in the same manner were encapsulated by a thin dense 
connective tissue layer where little cellular infiltration was observed. As for cardiac 
function, cardiac ECM-patched hearts exhibited no difference in the size or function 
of the ventricles compared to baseline values, while dilation was observed in Dacron-
patched hearts. The authors claim that it may be possible to achieve a contracting 
tissue by seeding stem cell-derived cardiomyocytes to this cardiac ECM patch 
(Wainwright et al. 2012), based on the success of a previous study where 
cardiomyocytes were seeded on SIS-ECM (Hata et al. 2010).  This cardiac ECM patch 
utilizing whole-heart decellularization has two major advantages; (1) it allows 
preservation of macroscopic and ultrastructural properties which would be desirable 
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in terms of mechanical strength of the patch, and (2) it could be used to repair large 
defects which is impossible in the case of using autologous tissue (Wainwright et al. 
2012). The limitation of this cardiac ECM patch approach could be the potential risk 
of immunological responses seen in xenograft implantation and the necessity to have 
a whole organ to be decellularized.  
      The approach of utilizing ECM hydrogels is advantageous in terms of creating an 
autologous ECM tissue engineering scaffold, as ECM hydrogels could be obtained 
from pieces of a tissue. However, for CHD treatment applications, where grafts in the 
form of sheets and conduits are required, its poor mechanical strength become a 
major challenge. A strategy to solidify the ECM hydrogel strong enough to form 
grafts is necessary. Although ECM solution is known to spontaneously gel via self-
assembly of ECM components (Brightman et al. 2000), the resulting gel is usually 
too soft to form a graft. A common approach to increase mechanical strength of a 
hydrogel is to add crosslinking agents. Examples of commonly used crosslinking 
agents include genipin (Sundararaghavan et al. 2008), transglutaminase (Greenberg, 
Birckbichler, and Rice 1991), and glutaraldehyde (Jayakrishnan and Jameela 1999). 
In a study carried out by Wassenaar and colleagues demonstrated that the addition 
of genipin, glutalaldehyde, and transglutaminase, at the concentration of 1 mM, 
0.05%, 120 mU/mL respectively, can increase the Young modulus of hydrogels 
without inducing cell toxicity (Wassenaar et al. 2016a). However, it is suggested that 
the crosslinking of these agents is still not sufficient to solidify the ECM hydrogels to 
form grafts (Williams et al. 2015). Strong crosslinking agents such as glutaraldehyde 
are known to have risks of cytotoxicity at higher concentrations (Jorge-Herrero et al. 
1999). Based on unsatisfactory experience with moderate crosslinking agents, 
Williams and colleagues developed an ECM-fibrin hydrogel using transglutaminase as 
a crosslinking agent. In their study, because the ECM interfered with the crosslinking 
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of fibrins, the concentration of ECM was low as 0.34 mg/mL while fibrin was used at 
3.3 mg/mL. Despite of the low ECM concentration, effect was observed on the 
differentiation of patient-derived cardiovascular progenitor cells when seeded on the 
ECM-fibrin hydrogel (Williams et al. 2015), which indicates the potential of this ECM 
hydrogel approach. Interestingly, difference in gene expression of cardiovascular 
differentiation markers (VWF and CNN1) was found when ECM-fibrin hydrogels 
prepared from ECM derived from neonatal and adult rats were compared (Williams et 
al. 2015). A potential cause for this would be the remodeling of ECM which is 
suggested to take place during aging. In a previous study carried out by Wiiliams et 
al., where a shotgun proteomics was performed on cardiac ECMs derived from fetal, 
neonatal, and adult rats, significant difference in ECM composition between neonatal 
and adult rats were found (Williams et al. 2014). 
      In summary, based on previous studies, cardiac ECM has potential advantages 
as a material for CTE. However, when considering utilization of ECM hydrogels 
obtained via decellularization of tissue pieces, for CHD treatment applications, a 
strategy to crosslink the hydrogel to form a graft material with sufficient mechanical 
strength is necessary. 
1.5.2 Scaffold-free tissue engineering approaches 
Scaffold-free approach is based on the self-assembly of cells. An example 
would be the cell sheet technique, where cells are first cultured on a surface coated 
with a temperature sensitive polymer (poly(N-isopropylacrylamide), PIPAAm). Once 
cells become connected to each other, the cultured cell sheet could be lift off by 
solubilizing the PIPAAm coating by simply lowering the temperature. Cell sheets 
could be stacked to fabricate a three-dimensional contractile tissue (Shimizu et al. 
2006) (Figure 3). Although the reported study was not specifically aiming for CHD 
treatment applications, it may have the potential to be utilized in the future. 
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Scaffold-free approach could be beneficial in terms of cell density, as the resulting 
sheet would be a compact myocardium similar to native tissue (Tee et al. 2010), as 
well as in terms of elimination of risk of immunological reaction to the foreign 
scaffold material.  
1.5.3 Decellularization-recellularization approach 
Decellularization-recellularization approach was reported by Ott et al. in 2008. 
Using cadaveric rat hearts, decellularization of whole heart was carried out by 
performing retrograde coronary perfusion of detergent solutions. The decellularized 
heart preserved the perfusable vascular architectures and structures of valves and 
chambers as well as the ECM components. The decellularized heart was subsequently 
seeded with cardiac or endothelial cells and successfully attained generation of pump 
function of the heart (Ott et al. 2008) (Figure 3). This approach has the potential to 
allow generation of artificial hearts using xenogeneic hearts, which may supply the 
shortage in donors for heart transplantation (Tee et al. 2010).  
1.5.4 Biotubes 
Another unique and promising approach is the biotube method. This is based 
on the tissue encapsulation phenomenon of foreign materials which occur in living 
bodies. Kato et al. reported a case of clinical application to a 2-year-old CHD patient. 
19 F drain tubes were embedded in the subcutaneous space, as a mold for biotube 
formation during a palliative surgery performed prior to defect repair. After 8 
months, the biotube was retrieved, and by cutting longitudinally, a tissue patch could 
be obtained. The patch was used for right pulmonary artery augmentation. 
Computed tomography (CT) images showed that after 9 months of implantation, the 
shape of the augmented pulmonary artery was well preserved, and no aneurysm 
formation nor stenotic change were observed (Kato et al. 2016).  
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1.6 Proteomics on ECM  
      To date, the intricate and dynamic cell-ECM interaction is not yet fully 
understood. Many studies have showed evidence of ECM-remodeling taking place 
under the influence of diseases. Therefore, a deeper understanding of the ECM 
proteome may provide valuable insights into pathophysiology, which may lead to 
improvement in treatment by allowing identification of novel prognostic and 
diagnostic markers and therapeutic opportunities (Naba et al. 2015). Additionally, 
having a better understanding of the ECM may aid development of bioinspired CTE 
approaches. Proteomics is a powerful technique to globally characterize the 
proteome and have been employed widely to understand the pathophysiology of 
various diseases. While many studies have been carried out to understand the ECM 
proteome and to study the influence of diseases in the field of cancer and 
cardiovascular diseases (Lindsey et al. 2016), only limited number of proteomic 
studies have been reported on CHD (Xia et al. 2013, Bond et al. 2018a and 2018b). 
Xia and colleagues have performed a shotgun proteomics on cardiac tissue obtained 
from CHD patients to understand the right ventricular (RV) remodeling seen among 
pediatric CHD patients by comparing tissues obtained from TOF and non-TOF 
patients. By gene ontology analysis, they found an increase in levels of glycolysis-
related proteins and a decrease in lipid-metabolism-related proteins in tissues 
obtained from TOF patients. Moreover, they found one of the ECM proteins, lumican, 
to be more abundant in non-TOF tissue compared to TOF tissue in the results of 
proteomics and subsequently confirmed by western blot (Xia et al. 2013). Lumican is 
known to be involved in regulation of collagen fiber assembly and fibrosis seen in 
ischemic and reperfused hearts (Fasso et al. 2008). Xia et al. also identified several 
other ECM proteins (biglycan, collagen alpha-1(XIV) chain, collagen alpha-6(VI) 
chain, EGF-containing fibulin-like extracellular matrix protein 1, emilin-2, fibulin-5, 
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fibrinogen beta chain, and fibrinogen gamma chain) as differentially expressed in 
TOF tissue in their shotgun proteomics results (Xia et al. 2013). It should be noted 
that the protein profile reported by Xia had some discrepancies compared to the 
results reported in previous studies using animal models. As a potential cause for 
this discrepancy, the authors pointed out the difference between human CHD and the 
traditional pulmonary artery banding animal model, in its pathophysiological process, 
time to progression, and molecular basis. They also referred to the potential 
influence caused by age, treatment, and other complications in the case of human 
subjects (Xia et al. 2013). Their findings depict the limitation in the usage of animal 
models to understand the dynamic nature of ECM and indicate the value of studying 
specimens obtained from human subjects. 
Bond and colleagues analyzed the RV tissues obtained from patients with VSD 
and TOF to compare the effect of different causes of RV disfunction. While VSD 
patients have RV hypertension due to the presence of left-to-right shunt, TOF 
patients have obstruction in RV. Gene ontology with enrichment analysis revealed 
that TOF patients had higher expression of proteins which are involved in contractile 
mechanisms. Some ECM proteins were identified in their studies, where none of 
them found to be differentially expressed (Bond et al. 2018a). The ECM protein 
identified in their study comprised approximately 1-2% of the total identified 
proteins, which seems to be lower than one could expect, given that collagen 
constitutes 30% of total protein mass of a multicellular animal (Frantz, Stewart, and 
Weaver 2010).  
Generally, when shotgun proteomics are performed on whole tissue, the 
predominance of intracellular constituents hamper identification and accurate 
quantification of ECM proteins (Lindsey et al. 2016). Therefore, to study ECM 
proteins by shotgun proteomics, depletion of abundant proteins (i.e. removal of 
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intracellular proteins) is usually required. Furthermore, proteomics on ECM is 
challenging due to the insoluble and tightly packed nature of ECM proteins which 
hinder sufficient protein extraction and digestion. To the author's knowledge, no 
studies have performed proteomics on cardiac ECM of pediatric CHD patients. 
1.7 Objective of this study 
This study consists of three parts; (1) decellularization of cardiac tissue 
obtained from pediatric CHD patients, (2) creation of ECM hydrogel as a CTE scaffold 
for CHD treatment and (3) establishment of a sample preparation procedure to 
perform proteomic analysis on cardiac ECM of pediatric CHD patients. To the author's 
knowledge, this would be the first attempt to carry out these tasks. 
In this study, cardiac ECM hydrogel sheets were created by combining ECM 
derived from pediatric CHD patient tissues and gelatin methacrylate (GelMA). The 
incorporation of patient-derived ECM is thought to help mimicking the cell-ECM 
interaction in the hydrogel, as it would contain various macromolecules which are 
present in the natural ECM. GelMA was selected as a crosslinking agent, as it has 
demonstrated its capability to fabricate a hydrogel sheet for CTE in previous studies 
carried out by Nikkhah laboratory (Navaei et al. 2016 and 2017 and Saini et al. 
2015). By utilizing photopolymerization of GelMA, hydrogels can be formed into a 
sheet that could be peeled off from the glass on which it was prepared. In a previous 
study, where GelMA was combined with gold nanorods (GNRs) to make a CTE 
scaffold, it was demonstrated that GNR-GelMA hydrogel exhibited good cell adhesion 
property and allowed cardiac tissue formation with organized sarcomeric - actinin 
structures and expression of connexin 43 gap junction protein. It was suggested that 
the incorporation of GNRs improved cell adhesion by increasing the stiffness of the 
hydrogel as well as by providing anchoring points for cells to adhere (Navaei et al. 
2016).  
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Based on the results of the previous studies on hydrogels of ECM and GelMA-
GNR, it was hypothesized that the ECM-GelMA hydrogel would exhibit improved cell 
retention compared to pristine GelMA hydrogel and would facilitate cardiac tissue 
formation. To investigate this hypothesis, ECM-GelMA hydrogels were created and 
the functionality was evaluated. Evaluation include cell retention, viability, 
expression of cardiac specific markers, and beating behavior of the cultured cells. In 
addition, based on the finding from the previous study where addition of GNRs to 
GelMA hydrogels enhanced cell maturation (Navaei et al. 2016 and 2017), the effect 
of incorporating GNR into ECM-GelMA hydrogel was investigated. 
      As for the establishment of sample preparation procedure for proteomic 
analysis, a previously reported approach which performs serial digestion using 
cyanogen bromide (CNBr) and trypsin was employed, and the quality of peptide 
generation was assessed by SDS-PAGE and matrix assisted laser 
desorption/ionization (MALDI).   
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CHAPTER 2 
DECELLULARIZATION OF CARDIAC TISSUE OBTAINED FROM PEDIATRIC CHD 
PATIENTS 
2.1 Introduction 
A large number of studies on decellularization of cardiac tissue has been 
reported, most of which is for animal tissues. Generally, decellularization could be 
carried out by treating the tissue with decellularization reagents. Chemical reagents, 
such as acids and bases, hypotonic and hypertonic solutions, chelating reagents and 
detergents (e.g. SDS) are used to lyse cell membranes and to remove cytosolic and 
genomic material (Hussey et al. 2018 and Crapo, Gilbert, and Badylak 2011). 
Alcohols (e.g. methanol and isopropyl alcohol) could be used for delipidization. In 
addition, proteases (e.g. trypsin, collagenase) and nucleases (e.g. ribonuclease 
(RNase) and deoxyribonuclease (DNase)) are used to digest cell debris and residual 
nucleic acids (Hussey et al. 2018 and Crapo, Gilbert, and Badylak 2011). Treatment 
with decellularization reagents could be carried out by either agitated immersion of 
the minced tissue, or in cases where a whole heart could be obtained, perfusion 
using the vessels could be an option (Ott et al. 2008). Four articles which carried out 
decellularization of human cardiac tissue were identified (Johnson et al. 2014 and 
2016, Godier-Furnémont et al. 2011, and Oberwallner et al. 2014). Johnson et al. 
carried out decellularization by treating the tissue with phosphate buffered saline 
(PBS) solution containing 1% SDS for several days followed by DNase/RNase 
treatment. Godier-Furnemont and colleagues on the other hand, first performed lysis 
using a solution containing 10mM of tris(hydroxymethyl)aminomethane-
hydrochloride (Tris-HCl) and 0.1% of ethylenediaminetetraacetic acid (EDTA) and 
then treated with 0.5% SDS solution followed by DNase/RNase treatment. 
Oberwallner et al. proposed a slightly modified version of Godier-Furnemont’s 
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group’s method, where fetal bovine serum (FBS) was used as a substitute for 
nuclease. All four reports used adult cardiac tissue and no reports on 
decellularization of cardiac tissue of pediatric patients were found. In this study, the 
protocol reported by Johnson et al. (Johnson et al. 2014, Johnson et al. 2016) was 
employed. 
Successful decellularization is usually evaluated based on the removal of 
cellular components, by measures including hematoxylin and eosin staining, 
immunostaining using 4',6-diamidino-2-phenylindole (DAPI), and quantification of 
residual double-stranded DNA (dsDNA). Multiple studies employ the threshold 
reported by Crapo et al, where <50 ng dsDNA/mg per dry weight ECM is defined as 
the threshold based on the potential to cause immunogenicity (Crapo, Gilbert, and 
Badylak 2011). The chemical reagents used in decellularization would affect ECM 
proteins as well, therefore, some portions of ECM components would be removed 
during decellularization. Therefore, optimal decellularization is a matter of balance 
between sufficient removal of cellular components to minimize risk of 
immunogenicity, and the retention of ECM components. Quantification of ECM 
components such as glycosaminoglycans, collagen and elastin are often carried out 
to assess the retention of ECM components (Oberwallner et al. 2014, Dijkman et al. 
2012, Schulte, Simionescu, and Simionescu 2013, Methe et al. 2014, and Wainwright 
et al. 2010). However, in this study, quantification of ECM components was not 
feasible due to the limited amount of ECM that could be obtained from each patient. 
Alternatively, ECM retention was qualitatively confirmed by Movat pentachrome 
staining and immunostaining. Movat pentachrome staining allows visualization of 
collagen, elastin, fibrin, and the nuclei. Immunostaining was performed for two 
components; collagen type I and laminin. Collagen type I is known to be the most 
abundant protein in the cardiac ECM (Villarreal and Kim 1998) and to serve as a 
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backbone of the ECM. Laminin is a basement membrane protein which is known to 
take part in regulation of cell adhesion, migration, differentiation and proliferation 
(Hamill et al. 2009). 
2.2 Materials and methods 
2.2.1 Decellularization of human cardiac tissue 
This study was approved by the Institutional Review Board (IRB) of Phoenix 
Children’s Hospital (PCH). Cardiac tissue was obtained from pediatric CHD patients 
who underwent a planned surgery or biopsy at PCH as part of standard treatment. 
Tissue of ventricular, including left and right, from total eight patients were obtained. 
Decellularization was carried out following an established protocol. (Johnson et al. 
2014 and 2016). Briefly, the tissues specimens were minced into 3-5 mm size pieces 
and treated with 1% SDS in Dulbecco's phosphate buffered saline (DPBS) solution 
for 6-8 days on a shaker at room 
temperature until the color of the tissues 
turns to pure white. After shaking in 
distilled water (DW) for 24 hours, the 
tissues were treated with a DNase/RNase 
solution for 24 hours at 37 °C to remove 
the residual cellular components. The 
DNase/RNase solution contained 40U/mL of 
DNase, 1U/mL of RNase, 40 mM of Tris-
HCl, 6mM of magnesium chloride, 1 mM of 
calcium chloride, and 10 mM of sodium 
chloride and the pH was confirmed to be 
between 7 to 8. The tissue was then 
washed with 1% SDS/DPBS for 24 hours to 
Figure 4  
Decellularization process of cardiac 
tissue 
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remove the residual DNase and RNase, followed by 24 hours of rinsing in DW. 
Finally, the tissue was thoroughly rinsed with DW, lyophilized, and stored at -80 °C 
until usage (Figure 4).  
2.2.2 Quantification of residual DNA 
DNA was extracted using NucleoSpin Tissue XS kit (Macherey-Nagel) following 
the manufacturer’s advice. 1mg of ECM was used and 8 L of protenase K was added 
twice (upon initiation of lysis and after 3 hours) for complete lysis of the sample. The 
extracted DNA was quantified using Quanti-iT Picogreen dsDNA assay (Invitrogen).  
2.2.3 Immunostaining for collagen type I and laminin 
For native tissue, cryopreservation was carried out using 30% sucrose prior to 
freezing. Cryosections of 5 m thickness were prepared from both, native and 
decellularized tissue. Fixation was performed before staining, by submerging the 
samples with 4% paraformaldehyde solution in DPBS for 15 minutes followed by 
three washes in DPBS. Primary monoclonal antibodies for collagen type I and laminin 
were obtained from Santa Cruz and Abcam, respectively. Secondary antibodies; goat 
anti-mouse Alexa Fluor-488 for collagen type I and goat anti-rabbit Alexa Fluor-555 
or 594 for laminin was purchased from Life Technologies. Permeabilization was 
performed using 0.1% Triton X-100 for 15 minutes, followed by five washes with 
DPBS. The samples were then blocked using 10% goat serum (Life Technologies). 
Next, primary antibodies for collagen type I and laminin, prepared at dilutions of 
1:100 and 1:200 respectively, were applied and samples were incubated overnight 
at 4 °C, followed by five washes with DPBS. Secondary antibodies were both 
prepared at dilution of 1:200 and applied for 1 hour. After five washes with DPBS, 
DAPI (Life Technologies, 1:1000 dilution in DPBS) staining was performed and 
fluorescent images were taken using Zeiss Axio Observer Z1 at 10x objective.  
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2.2.4 Histological evaluation 
Preparation of 5 m cryosections and fixation was performed in the same 
manner as described in section 2.2.3. Movat pentachrome staining was performed 
using a kit (Cancer Diagnostics) following the manufacturer’s advice. Images were 
obtained using Nikon Elipse TE300 Inverted Video Microscope (Nikon). 
2.3 Results and discussion 
Total of eight tissue specimens obtained from PCH were decellularized. DNA 
quantification was performed in all samples, except for one which the amount of 
obtained decellularized tissue was too small. In all seven decellularized samples, the 
amount of residual dsDNA was found to be below 50 ng per 1 mg of dry ECM, 
indicating sufficient removal of cellular components. Results of immunostaining were 
in accordance, as no nuclei could be identified in DAPI staining nor Movat 
pentachrome staining in decellularized tissue (Figure 5 and 6).  
      Retention of ECM components were assessed by immunostaining and Movat 
pentachrome staining. Immunostaining was performed for collagen type I and 
laminin, as these proteins are known to be one of the main components of the 
interstitial ECM and basal lamina, respectively. Both are known to have motifs to 
which a vast range of macromolecules could bind to (Lodish et al. 2000), therefore, 
both are important components to facilitate cell-ECM interaction. As seen in Figure 
5, although the fine structures observed in native tissue is lost after 
decellularization, both collagen type I and laminin appeared to be present in 
decellularized tissue. These observations are in accordance with previous studies 
where decellularization was performed using SDS (Ott et al. 2008, Godier-Furnémont 
et al. 2011, Oberwallner et al. 2014, and Singelyn et al. 2009). In Movat 
pentachrome staining (Figure 6), removal of muscle cells (round components 
stained red) and retention of collagen (stained yellow) were also observed. Fibrins 
  30 
(small fibrils stained red) which were identified in native tissue could not be found in 
decellularized tissue. It is not clear whether this indicate the loss of fibrin during 
decellularization procedure, or it is due to the sample preparation procedure for 
staining. As seen in Figure 6A, fibrins are small fibrils which is not homogeneously 
distributed, thus, identification could depend on the location where cryosections were 
Figure 5 Representative fluorescent images of native (A) and 
decellularized tissue (B). Laminin, collagen type I, and nuclei are stained 
red, green, and blue, respectively. Scale bars represent 50 m.  
 
Figure 6 Representative images of Movat pentachrome staining of native 
(A) and decellularized tissue (B). Collagen are stained yellow and muscle 
and fibrin are stained red. The blue mesh-like structure is agarose which 
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obtained. In addition, while native tissue is sectioned in a manner which the original 
structure is preserved as much as possible, decellularized tissue have undergone 
extensive washes and lyophilization prior to sectioning and staining. Considering 
these factors, it was difficult to assess the fibrin retention based on staining.  
In summary, sufficient removal of cellular components was confirmed in the 
decellularized tissues. Collagen and laminin appeared to be present after 
decelluarization, however, the retention of ECM components could not be assessed 
sufficiently in the staining experiments carried out. It could be expected that if 
proteomic analysis could be performed in the future, that could be an alternative 
method to confirm retention of ECM proteins. 
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CHAPTER 3 
FABRICATION OF ECM-INCORPORATED GELATIN-BASED HYDROGEL 
3.1 Introduction 
        As discussed earlier, utilization of ECM hydrogel for CHD treatment applications 
requires a strategy to crosslink the ECM hydrogel to form a graft. Moderate 
crosslinking agents which are often used, such as genipin (Sundararaghavan et al. 
2008) and transglutaminase (Greenberg, Birckbichler, and Rice 1991), are suggested 
to be not sufficient to increase the mechanical stiffness of the hydrogel (Williams et 
al. 2015). Strong crosslinking agents (e.g. glutaraldehyde (Jayakrishnan and 
Jameela 1999)) are known to have higher risk of cell toxicity at high concentrations.  
      GelMA was selected as a crosslinking agent for this study, as it has multiple 
advantageous aspects as a material for tissue engineering applications. First, it is 
biocompatible. As gelatin is denatured collagen, it retains many of the bioactive 
features of collagen, including cell binding motifs and MMP-sensitive degradation 
cites (Nichol et al. 2010), which are both important in facilitating cell-ECM 
interaction. In multiple previous studies carried out by Nikkhah laboratory, GelMA 
hydrogel successfully accommodated cardiac cells allowing them to form a cardiac 
tissue with contractile properties (Navaei et al. 2016 and 2017 and Saini et al. 
2015). Furthermore, long-term (49 days) cell viability has been confirmed in an 
experiment using porcine aortic valvular interstitial cells (Benton et al. 2009). 
Second, the methacrylate group allow photopolymerization and the physical 
properties (mechanical stiffness and swelling property) of the resulting hydrogel can 
readily be tuned by the adjusting the degree of methacrylation during synthesis, or 
the GelMA concentration in the hydrogel (Nichol et al. 2010). In this study, GelMA 
with high degree of methacrylation (96.41 ± 1.54%) (data not shown) was used at 
the concentration of 5%. This concentration was chosen considering the results of a 
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previous study which found a decrease in cell viability when higher concentrations 
(10 and 15%) were used (Nichol et al. 2010), as well as the results of a preliminary 
experiment where 2.5% was found insufficient to form a sheet structure. 
3.2 Materials and method 
3.2.1 Preparation of solubilized ECM 
Cardiac tissues (left ventricle and left ventricular septum) obtained from one 
pediatric CHD patient was used for this experiment. The tissue was snap frozen upon 
arrival from PCH. Frozen tissue was thawed and cut into 3-5 mm pieces, and 
decellularization was carried out in the same manner as described in section 2.2.1. 
To 10 mg of lyophilized ECM, pepsin solution (1 mg/mL in DW) was added and the 
ECM was homogenized using Precellys 24 and Hard Tissue Homogenizing CK28 
(Bertin Instruments). The ECM homogenate was transferred to a scintillation vial 
with a stirrer and 8.3 uL of 1M hydrochloric acid (HCl) was added. Final volume was 
adjusted to 1 mL and digestion was carried out for 48-72 hours at room temperature 
under stirring, until the ECM particles disappeared. Upon completion of digestion, the 
solubilized ECM was neutralized with 1M NaOH and aliquoted into centrifuge tubes. 
Finally, the aliquots of solubilized ECM were frozen at -80 °C followed by 
lyophilization and stored at -80 °C until usage. 
3.2.2 Synthesis of Gelatin methacrylate 
GelMA was synthesized following previously established protocol (Nichol et al. 
2010 and Navae et al. 2016 and 2017). Briefly, type A gelatin (Sigma-Aldrich) (10% 
w/v) was dissolved in DPBS at 50 °C. This was followed by dropwise addition of 8% 
v/v methacrylic anhydride (Sigma) and the solution was stirred for 3 h at 50 °C. The 
methacrylation reaction was terminated by diluting the solution with DPBS at 50 °C. 
The final solution was purified by dialysis using a 12-14 kDa molecular weight cutoff 
dialysis tube. Dialysis was performed at 45 °C in DW under stirring for 7 days. 
  34 
Finally, the dialyzed solution was filtered using a 0.2 m membrane, followed by 
lyophilization.  
3.2.3 Synthesis of gold nanorods 
GNRs were synthesized following an established protocol of seed mediated 
growth method (Nikoobakht and El-Sayed 2003 and Navaei et al. 2016 and 2017). 
Briefly, 2 mL of hydrogen tetrachloroaurate (HAuCl4) aqueous (0.5 mM in DIW) 
solution was first mixed with 2 mL of 0.2 M hexadecyltrimethylammonium bromide 
(CTAB) solution (0.2 M in DW), resulting in a deep yellow solution. 240 L of ice-cold 
sodium borohydride (NaBH4) dissolved in DW was added at once to the solution 
under stirring and the mixture was kept stirred for 2 minutes. Immediately after 
adding NaBH4, the color of the solution turned from deep yellow to light brown-
yellow, which indicated the formation of gold nanoparticles (seed solution). The seed 
solution was incubated for at least 4 hours at 30 °C. Next, the growth solution was 
prepared in a falcon tube by adding 1.12 mL of silver nitrate (AgNO3) (4 mM in DW) 
to 20 mL CTAB (0.2 M in DW) followed by the addition of HAuCl4 (1 mM in DW) 
solution 20 mL, resulting in a deep yellow solution. 280 L of ascorbic acid solution 
(13.88 mg in 1 mL DW) was added and the solution was mixed by inverting the 
falcon tube, turning the solution colorless. Finally, 48 L of seed solution was added 
into the growth solution at 30 °C and kept incubated overnight. The color of solution 
turns to brown-red over a period of half an hour, indicating the formation of GNRs. 
Based on transmission electron microscopy images, the average aspect ratio of the 
synthesized GNRs was calculated to be approximately 3.15 (data not shown). To 
remove excess CTAB, the synthesized GNRs colloid was centrifuged at 12,000 rpm 
for 10 min and washed with DPBS twice.  
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3.2.4 Preparation of ECM-GelMA-GNR hybrid hydrogels 
First, photoinitiatior ((2-hydroxy-1-(4-(hydroxyethoxy) phenyl)-2-methyl-1-
propanone; Sigma) was dissolved in DPBS at the concentration of 0.5% w/v. This 
solution was added to lyophilized GelMA (final concentration 5% w/v) and the 
mixture was kept at 80 °C until complete dissolution was confirmed. The GelMA 
solution was then kept at 40 °C until usage. For ECM-GelMA hydrogels, the GelMA 
solution was added to lyophilized ECM to result in final concentration of 2.4% of 
ECM. 1.2%ECM-GelMA solution was prepared by diluting the 2.4%ECM-GelMA 
solution with GelMA solution. For the GNR-incorporated hydrogels, necessary amount 
of GNRs to result in a final concentration of 1 mg/mL in the hydrogel was aliquoted 
and centrifuged at 12,000 rpm for 10 minutes. The supernatant was removed and 
hydrogel solutions (GelMA or ECM-GelMA) were added. The mixture was mixed 
thoroughly by votexing to disperse the GNRs.  
Hydrogel constructs were prepared via photopolymerization. First, 6 L of the 
ECM-GelMA-GNR mixture was pipetted on a plastic surface, between two 150 m tall 
spacers, and covered with a glass slide coated with 3-(trimethoxysilyl) propyl 
methacrylate (TMSPMA; Sigma). The construct was formed by exposing this setup to 
UV light (800 mW, 360–480 nm). When the TMSPMA coated glass are removed, the 
hydrogel construct would detach from the plastic surface and the spacers, resulting 
in the hydrogel to be retrieved attached on the TMSPMA coated glass. 
Prior to cell culture experiments, the constructs were treated with 2% v/v 
penicillin-streptomycin (100 units/mL) in DPBS for 10 min twice followed by 10 min 
incubation in DPBS and another 10 min incubation in cardiac cell culture medium. 
Cell culture medium used in this study contained Dulbecco’s modified eagle medium 
(DMEM) (Gibco), FBS (10%) (Gibco), L-Glutamine (1%) (Gibco), and penicillin-
streptomycin (100 units/mL) (1%). 
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3.2.5 Cardiomyocytes isolation and culture 
Cardiomyocytes were obtained from two days old neonatal rats following an 
established protocol approved by Institution of Animal Care (IACUC) at Arizona State 
University (ASU) and based on previous extensive expertise of Nikkhah laboratory 
(Navaei et al. 2016 and 2017 and Saini et al. 2015). Briefly, the thorax of the 
neonatal rats was opened, and hearts were harvested. Upon removing the atria, the 
hearts were cut into 3–4 medium sized pieces and placed in 0.05% trypsin solution 
(without EDTA; Gibco) prepared in Hank’s balanced salt solution (HBSS; Gibco) for 
approximately 16 hours at 4 °C with continuous gentle shaking. Next, the heart 
pieces were neutralized in cell culture medium and further treated with type II 
collagenase, yielding a mixture of cardiomyocytes and cardiac fibroblasts. The cell 
suspension was then preplated in T-175 flasks to isolate cardiomyocytes. After an 
hour of preplating, most of the cardiac fibroblasts attach to the flask, while 
cardiomyocytes remain unattached. Unattached cells were collected and used for 
experiments.  
Hydrogel constructs were placed in a 48-well plate and harvested 
cardiomyocytes were seeded on top (6.0 x 105 cells/well). Cells were cultured in the 
cardiac culture medium for 8 days. Culture medium was changed every other day.  
3.2.6 Evaluation of cell of retention and survival 
Cell retention was evaluated by the fraction area of the hydrogel covered by 
cells at day 1 of culture. 10x magnification images were obtained from at least 3 
individual locations per construct. More than quadruplicate samples were evaluated 
for each condition per experiment, and experiments were repeated 4 times. 
Cell viability after 8 days of culture was evaluated using standard Live/Dead 
assay kit (Life technologies, USA) following the manufacturer’s instruction. A solution 
containing 0.5 µL of calcein AM and 2 L of ethidium homodimer in 1 mL of warm 
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DPBS was applied to the cells for 30 min. Fluorescent z-stack images at 10× 
magnification were taken to visualize live cells (stained green) and dead cells 
(stained red). Cell viability was calculated by dividing the number of live cells by the 
total number of cells.  
All images were acquired using a phase-contrast/fluorescence microscope 
(Zeiss Axio Observer Z1) equipped with Apotome, and subsequent analysis 
(calculation of fraction area covered by cells and counting of live/dead cells) were 
performed using NIH ImageJ software.  
3.2.7 Analysis of beating behavior of the cells 
The spontaneous beating of cardiomyocytes was monitored from day 1 to day 
8 of culture. Using a phase-contrast microscope (Zeiss Axio Observer Z1), a 30 
seconds-long video was recorded for each sample at 2.5x magnification. 
Representative beating signals were acquired from images of five individual locations 
using a custom written MATLAB code used in a previous study (Navaei et al. 2016). 
3.2.8 Immunostaining for cardiomyocyte specific markers (sarcomeric -
actinin and connexin 43) 
Primary monoclonal antibodies for sarcomeric -actinin and connexin-43 were 
obtained from Sigma and Abcam, respectively. The secondary antibodies; goat anti-
mouse Alexa Fluor-488 for sarcomeric -actinin and goat anti-rabbit Alexa Fluor-555 
for connexin 43 were both purchased from Life Technologies. At day 8, 
cardiomyocytes were fixed with 4% paraformaldehyde for 30 min, followed by five 
washes in DPBS. Permeabilization was carried out by applying 0.5% Triton X-100 for 
45 min at room temperature. Next, cells were blocked in 10% goat serum for 2 
hours at room temperature. Primary antibodies for both sarcomeric -actinin and 
connexin 43 were prepared in 10% goat serum at 1:100 dilution. After applying the 
primary antibodies, samples were kept at 4 °C overnight followed by five washes in 
  38 
DPBS. As for secondary antibodies, Alexa Fluor-488 anti-mouse and Alexa Fluor-555 
anti-rabbit were both prepared at 1:200 dilution in 10% goat serum (Life 
Technologies) and applied for 1 hour. Cells were then washed three times with DPBS. 
Finally, cells were stained with DAPI (Life Technologies, 1:1000 dilution in DPBS) for 
10 minutes to label the nucleus followed by three washes in DPBS. Fluorescent z-
stack images were obtained using a fluorescence microscope (Zeiss Axio Observer 
Z1) equipped with Apotome at 40x- objective.  
3.2.9 Statistical analysis 
All the data collected in this study were analyzed using one-way ANOVA 
analyses and reported as mean ± standard deviation (SD). Turkey’s multiple 
comparison with a p-value < 0.05 was employed to evaluate statistically significant 
difference between groups. All statistical analyses were performed using GraphPad 
Prism (v.6, GraphPad). 
3.3 Results and discussion 
3.3.1 Fabrication of ECM-GelMA hydrogel 
The incorporation of neither ECM (1.2% or 2.4%) nor the GNRs (1 mg/mL) 
interfered with the crosslinking of GelMA, and constructs of six conditions were 
fabricated successfully. The conditions will be referred as stated in parenthesis 
hereinafter; Pristine 5% GelMA hydrogel (5%GelMA), 5% GelMA hydrogel containing 
1 mg/mL of GNRs (GelMA-GNR), 5% GelMA hydrogel containing 1.2% of ECM 
(1.2%ECM-GelMA), 1.2%ECM-GelMA containing 1 mg/mL of GNRs (1.2%ECM-
GelMA-GNR), 5% GelMA hydrogel containing 2.4% of ECM (2.4%ECM-GelMA), 
2.4%ECM-GelMA containing 1 mg/mL of GNRs (2.4%ECM-GelMA-GNR). The hydrogel 
constructs were prepared to have the height of 150 m, and the diameter was 
approximately 5 mm among all conditions. 
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3.3.2 Cell retention and viability 
Cell retention was evaluated at day 1 of culture, based on the fraction area of 
hydrogel covered by cells. Figure 7 shows the results of four repeated experiments. 
A large between-experiment variability was observed, and no statistically significant 
difference was found among the six conditions. However, in 3 out of 4 experiments, 
ECM-incorporated hydrogels showed significantly higher cell retention compared to 
pristine GelMA, which may indicate that the addition of ECM may have a slight effect 
on cell retention of the hydrogel. More experiments may be necessary to assess 
whether that trend could be constantly observed.  
The viability at day 8 also exhibited a large variability between experiments 
and no statistically significant difference was found (Figure 8). Although an almost 
significant difference was found when comparing ECM2.4%-GelMA and ECM2.4%- 
GelMA-GNR (p=0.0634), given the large variability seen in the cell retention in four 
experiments as shown in Figure 7, as well as the observations noted during 
experiments where viability tend to be low when cell retention was low, it was 
deemed to be inappropriate to assess the effect at this point with small number of 
experiments (n=3).  
The large between-experiment variability can be attributed to several factors. 
First would be the quality of cardiomyocytes which could vary by the quality of cell 
isolation.  Second would be the between-batch variation in the composition of 
solubilized ECM. Although the solubilized ECM used in the experiments were all 
prepared from the tissue obtained from a single patient, decellularization and 
solubilization were carried out in several batches. In addition, the specimen 
contained the left ventricle as well as the left ventricular septum, and ECM 
composition could differ depending on which part of the tissue was used. Protein 
removal which takes place during decellularization as well as the digestion efficiency  
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Figure 8 Viability of cardiomyocytes seeded on ECM-GelMA-GNR hydrogels 
at day 8 of cell culture. 
Figure 7 Cell retention. Cell retention is calculated by the fraction area of 
hydrogels covered by cardiomyocytes at day 1. 
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using pepsin could be impacted by the variability in the ECM composition of the 
sample. Batch-to-batch variability is a well-known limitation in ECM-based materials 
(Romano et al. 2011, Serban and Prestwich 2008). Third is the heterogenous nature 
of ECM hydrogels. As mentioned earlier, spontaneous gelation of ECM hydrogels 
could occur at 37 °C via self-assembly of ECM components. During preparation of 
ECM-GelMA-GNR hydrogels, GelMA was warmed to 40 °C prior to mixing with ECM. 
Therefore, spontaneous gelation could occur during mixing the hydrogel solution 
prior to photo-crosslinking. During the experiment, it was observed that some of the 
hydrogel constructs contained few small pieces of ECM.  
In summary, cell retention and viability were found to have a large between-
experiment variability and the results were inconclusive at this point. However, it 
would be worth noting that the cells appeared to spread more in hydrogels 
containing ECM and/or GNRs compared to pristine GelMA hydrogel (Figure 9), which 
observation was consistent among the four experiments carried out. 
 
  
Figure 9 Representative phase-contrast images of the hydrogels at day 8 of 
cell culture. Scale bars represent 100 m. 
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3.3.3 Assessment of spontaneous beating behavior  
Beating is a phenomenon observed during culture of cardiomyocytes. At initial 
time points of cell culture, cardiomyocytes individually beat spontaneously. As cells 
spread and connect to each other, gap junctions will be formed and cell-cell coupling 
will be established. By cell-cell coupling, cardiomyocytes become able to beat in a 
synchronous manner (i.e. cardiomyocytes at different locations of the hydrogel beat 
synchronously), which gives the appearance of the hydrogel as a “spontaneously 
beating sheet”. Thus, the occurrence of synchronous beating could indicate the 
presence of cell-cell coupling. Establishment of cell-cell coupling would be a sign of 
cell maturation as it allows the connected cells (i.e. formed tissue) to beat 
synchronously in response to external electrical stimuli, just as the native heart 
tissue. However, it should be noted that spontaneous beating involves stochastic 
factors, such as the presence of pacemaker cells. Therefore, the lack of spontaneous 
beating does not necessarily mean insufficient cell-cell coupling. Figure 10 shows 
representative beating signals of spontaneous beating observed at day 8. Beating 
signals were obtained from five individual locations from each construct. Although 
variability was observed in beating behavior, such as frequency of beating and the 
fraction of hydrogel beating, majority of the hydrogels exhibited synchronous beating 
at day 8. Interestingly, when ECM and GNRs were incorporated, the frequency of 
spontaneous beating tend to be lower compared to the cases where either ECM or 
GNRs was incorporated. One potential cause could be the difference in cell adhesion 
and spreading. During experiments, it was observed that the ECM-GelMA hydrogels 
tend to have more cell clusters compared to ECM-GelMA-GNR hydrogels, which could 
potentially be indicating difference in cell-ECM interaction. Further study would be 
necessary to investigate what factors (e.g. anchoring points, stiffness of hydrogel) 
may have caused this difference. 







5%GelMA 1.2%ECM-GelMA  2.4%ECM-GelMA  
GelMA-GNR 1.2%ECM-GelMA-GNR  2.4%ECM 2.4%-GelMA-GNR  
Figure 10 Representative spontaneous beating signals at day 8 of 
cell culture. Beating signals obtained from five individual location are 
shown. 
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3.3.4 Expression of sarcomeric -actinin and connexin 43 
Phenotype of cultured cardiomyocytes was assessed by immunostaining for 
cardiac specific markers, sarcomeric -actinin and connexin 43. Sarcomeric -actinin 
takes part in the actin-myosin contraction complex, and connexin 43 is a gap 
junction protein known to be responsible for synchronous contraction of the cells 
(Oyamada et al. 1994). As can be seen in Figure 11, organized sarcomeric -actinin 
structures and expression of connexin 43 were evident in hydrogels containing ECM 
and/or GNRs. Although there was variability, presumably due to the variability in cell 
spreading, the trend where expressions of cardiac specific markers were evident in 
ECM- and/or GNRs-incorporated hydrogels compared to pristine GelMA hydrogel, was 
constantly observed. 
The beneficial effect of adding GNRs to GelMA hydrogel was in accordance with 
the results of the previous studies (Navaei et al. 2016 and 2017). Multiple previous 
Figure 11 Representative fluorescent images of immunostaining for 
cardiac specific markers.  Sarcomeric -actinn are stained red and 
connexin 43 are stained green. Scale bars represent 25 m. 
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studies have reported that the addition of nanomaterials to polymer hydrogels would 
enhance cell maturation, where alteration in nano-scale surface topology and 
mechanical strength of the scaffold polymer have been suggested to be potential 
causes. Particularly, in the case of incorporating conductive nanomaterials to non-
conductive polymer hydrogels, improved conductivity is thought to be another factor 
which may affect cell maturation, as it may facilitate electrical stimuli propagation in 
the hydrogel (Dvir et al. 2011, You et al. 2011, Pok et al. 2014, Li et al. 2014, and 
Navaei et al. 2016 and 2017). ECM, as described earlier, contains various proteins 
that could serve as motifs for cells to adhere, as well as regulators of cellular 
processes. Therefore, the higher expression of sarcomeric -actinin and connexin 43 
observed in hydrogels containing ECM and/or GNRs seems to be expectable and 
reasonable. 
It should be noted that the expression of sarcomeric -actinin and connexin 43 
appeared to be comparable among hydrogels containing both ECM and GNRs, and 
those containing either of ECM or GNRs, despite the difference seen in spontaneous 
beating behavior. As shown in Figure 10, the later exhibited synchronous and 
periodical spontaneous beating, which was not prominent in the former. This 
indicates that the lack of spontaneous synchronous beating is not due to insufficient 
cell maturation and cell-cell coupling. Further study would be necessary to 
investigate the cause of the different beating behaviors. There could be a possibility 
that the combination of three components (GelMA, ECM, and GNRs) may have 
affected cellular processes responsible for cell spreading as well as spontaneous 
beating, in a different manner from two-component hydrogels (GelMA-ECM and 
GelMA-GNR). In addition, interactions between ECM and GNRs could be another 
possibility. 
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CHAPTER 4 
OPTIMIZATION OF SAMPLE PREPARATION FOR PROTEOMICS 
4.1 Introduction 
Proteomics on ECM is a challenging task due to the characteristic features of 
ECM proteins, such as high molecular weight of the proteins and the presence of 
covalent protein crosslinks by which the ECM proteins become insoluble and difficult 
to extract (Hansen et al. 2015). Protein extraction from tissue materials, where 
proteins are already assembled into stable structures, is even more challenging. 
Sufficient extraction and digestion of ECM proteins are crucial for successful ECM 
proteomics (Hansen et al. 2015). While protein extraction using chaotropes and 
detergents is the most common method in bottom-up proteomics, various 
approaches, such as serial extraction using solutions of salts, chaotropes, and 
detergents (Barallobre-Barreiro et al. 2012 and Suna et al. 2018), ultra-sonication-
assisted digestion (Hansen et al. 2015), and CNBr cleavage (Kraft, Mills, and Dratz 
2001, Johnson et al. 2014 and 2016, and Vit et al. 2016) have been reported to 
address the difficulties in protein extraction. Hill et al., who aimed to accurately 
characterize the ECM, pointed out that protein extraction using chaotropes and 
detergents constantly yield an insoluble protein-containing pellet, which would be 
discarded prior to trypsin digestion. By employing chemical digestion with CNBr, they 
found nearly 80% of the fibrillar proteins (e.g. collagen type I, fibrillin-1) within the 
insoluble pellet remaining unextracted by chaotropes (Figure 12, Hill et al. 2015). 
The use of CNBr has several advantages. First, CNBr specifically cleaves proteins at 
the C-terminal of methionine (Vit et al. 2016), which specificity is important in 
proteomics. Second, ECM proteins include tightly packed hydrophobic proteins which 
could hinder enzymatic digestion facilitated by proteases (Hill et al. 2015 and Hansen 
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et al. 2015). This would not be a problem in the case of chemical digestion (Hill et al. 
2015). Thirdly, as methionine cleavage sites are typically located in hydrophobic 
domains, cleavage at these points reduces the size of the hydrophobic fragments 
(Kraft, Mills, and Dratz 2001), and thus, could potentially improve protein extraction. 
      Building on the findings of the study carried out by Hill et al., Johnson and 
colleagues carried out proteomics on cardiac ECM of human adults by first 
decellularizing the tissue followed by serial digestion using CNBr and trypsin, and 
successfully characterized the cardiac ECM (Johnson et al. 2016).  
      In this study, the protocol reported by Johnson et al. was adopted to perform 
proteomics on cardiac ECM of pediatric CHD patients. Since it is suggested that ECM 
composition differ by age and the influence from diseases (Kraft, Mills, and Dratz 
2001 and Williams 2014), it is unclear whether this protocol which was optimized for 
adult cardiac tissue would be applicable for pediatric CHD patient tissue as well. As a 
first step, whether the same protocol can generate peptides viable for proteomic 
analysis was assessed by SDS-PAGE and MALDI.  
  
Figure 12 Effectiveness of protein extraction method. Cellular proteins are 
extracted using a high salt CHAPS buffer and mechanical tissue homogenization, 
solubleECM (sECM) is extracted using a 6 M urea buffer with vortexing and 
insolubleECM (iECM) is extracted after chemical digestion. Adopted by (Hill et al. 
2015) with permission from ELSEVIER. 
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4.2 Materials and methods 
4.2.1 Sample preparation for MALDI 
      Tissue obtained from one patient was used in this experiment. Tissue was snap 
frozen upon arrival from PCH and decellularized in the same manner as described in 
section 2.2.1, lyophilized and kept at -80 °C until usage.  
      Upon chemical digestion, 2-4 mg of lyophilized ECM was homogenized in 250-
700 L of water. Mixture of CNBr and trifluoroacetic acid (TFA) was added to the 
homogenate to result in a final concentration of 100 mM CNBr and 86% TFA. 
Chemical digestion was carried out at room temperature in dark for 24 hours. 
Subsequently, the volume of the sample was reduced under vacuum, and solvent 
exchange with water was performed three times. The resulting peptides were 
dissolved in water and the peptide concentration was measured by BCA assay 
(Thermofisher Scientific).  
      Trypsin digestion was performed by in-solution digestion, after chemical 
digestion. First, 50 g of peptide was aliquoted and the solvent was removed using 
Speed-Vac. Next, the peptides were re-dissolved in 100 L of 8M Urea in 50 mM 
Triethylammonium bicarbonate (TEAB) and 200 mM tris(2-carboxyethyl)phosphine 
(TCEP) was added to the final concentration of 10 mM. Reduction was carried out at 
55 °C for 1 hour. The samples were then alkylated with iodoacetamide (final 
concentration 17 mM) at room temperature for 30 minutes in dark. Prior to trypsin 
digestion, the samples were diluted 5-times by adding 100 mM TEAB. 1 g of trypsin 
was added to 10 g of protein and digestion was carried out overnight at 37 °C. 
Digestion was quenched by the addition of 10% TFA to adjust the sample to pH 
lower than 2. The digested peptides were desalted using a desalting column 
(Thermofisher Scientific) prior to MALDI analysis. MALDI was performed using AB 
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SCIEX 4800 MALDI TOF/TOF MS mass spectrometer (SCIEX) and carried out by the 
Mass Spectrometry Core Facility of Arizona State University.  
4.2.2 SDS-PAGE 
      SDS-PAGE was performed with a 15% Tris-Glycine gel. 10-20 g of protein was 
loaded per well.  
4.3 Results and discussion 
As shown in Figure 13, the extracted ECM proteins mainly consist of high 
molecular weight proteins (higher than 100 kDa) (lane A). The standard in-solution 
trypsin digestion (i.e. protein extraction with urea followed by reduction, alkylation 
and trypsin digestion) (lane B) was able to generate peptides. However, the size 
appears to range at 5-40 kDa, which indicates that the generated peptides were 
large. Generally, peptides smaller than 10 kDa (preferably below 5 kDa) are required 
to perform mass spectrometry. In addition, during treating the ECM by this method, 
Figure 13 Comparison of digestion efficiency by SDS-PAGE. Undigested 
proteins extracted using 8M urea (A), digested with trypsin (B), treated with 
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after protein extraction, an insoluble pellet was observed, which was in accordance 
with the observation reported by Hill et al. (Hill et al. 2015). This could be due to the 
tightly packed structure of ECM proteins as referred in previous studies (Hill et al. 
2015 and Hansen et al. 2015). CNBr cleavage was able to break down the proteins 
to some extent and generated peptides with a wide range of size (lane C). Since the 
SDS-PAGE result revealed the presence of small peptides (<10 kDa) in the CNBr-
cleaved samples, subsequent trypsin digestion was carried out by in-solution 
digestion instead of the filter-aided sample preparation (FASP) protocol which was 
employed in the protocol reported by Johnson et al. (Johnson et al. 2014 and 2016) 
to minimize peptide loss (i.e. the small peptides would be lost as flow-through during 
the centrifugation performed in FASP protocol to remove unwanted reagents). Serial 
digestion using CNBr and trypsin (lane D) generated smaller peptides compared to 
the case of performing CNBr-cleavage or trypsin digestion solely. Although sizes of 
peptides ranged up to 25 kDa, the majority appeared to be below 10 kDa, therefore, 
the sample was subjected to MALDI analysis to confirm the presence of peptides. 
The mass spectrum obtained by MALDI is shown in Figure 14. Although some peaks 
were detected, it was concluded that the digestion protocol requires further 
optimization, for the following reasons. 
To validate this serial digestion method, bovine serum albumin (BSA) was 
treated in the same manner as the actual sample and evaluated by SDS-PAGE and 
MALDI (Figure 15). The SDS-PAGE exhibited a band below 10 kDa. Accordingly, 
more peaks were identified in MALDI, compared to the case of ECM. However, when 
a peptide mass fingerprint database search was attempted, BSA did not come up in 
the results. One potential cause could be low digestion efficiency. As the 3 large 
peaks seen at 1481, 1568, and 2046 (m/z) matches with the peaks in theoretical 
spectra, it could be interpreted that the cleavage by CNBr and trypsin is taking place, 
  51 
however, the efficiency could be low resulting in low sequence coverage. Therefore, 
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CHAPTER 5 
CONCLUSION AND FUTURE WORK 
5.1 Conclusion 
To the best of the author’s knowledge, this is the first study to perform the 
followings; (1) decellularization of cardiac tissue obtained from pediatric CHD 
patients, (2) development of a patient-derived ECM and GNR-incorporated hydrogel 
for CTE applications, and (3) attempt made to prepare samples for proteomic 
analysis on cardiac ECM of pediatric CHD patients.  
First, as for decellularization, it was confirmed that the cellular component was 
successfully removed by the procedures carried out in this study. Due to the limited 
amount of ECM sample that could be obtained by decellularization, quantitative 
evaluation on retention of ECM components was not feasible and qualitative 
assessment (histology and immunostaining) were able to identify only few ECM 
components (collagen and laminin). Nonetheless, the retention of those ECM 
components was confirmed, and the observations were in accordance with those 
reported in other analogous studies (Ott et al. 2008, Godier-Furnémont et al. 2011, 
Oberwallner et al. 2014, and Singelyn et al. 2009). If proteomics could be carried out 
in the future, it may serve as an alternative method to confirm retention of ECM 
proteins. 
Next, ECM-GelMA-GNR hydrogel sheet was successfully created. 
Immunostaining for cardiac-specific markers revealed organized sarcomeric -actinin 
structure and connexin 43 expression in the hydrogels containing ECM and GelMA, 
which indicated enhancement in cell maturation under the presence of these 
components. These results indicated the potential of ECM-GelMA-GNR hydrogels as a 
tissue engineering scaffold.  
  53 
Interestingly, the spontaneous beating behavior of the cultured cells at day 8 
was different depending on composition of the hydrogel. Given that signs of cell 
maturation and gap junction formation were confirmed by immunostaining in the 
hydrogels which did not beat, it could be speculated that the hydrogel composition 
may have influenced cellular processes responsible for cell spreading and 
spontaneous beating (i.e. contraction of cells). Further studies would be necessary to 
understand the mechanism of this interesting phenomenon. 
As for evaluation on cell retention and variability, results were inconclusive as a 
large between-experiment variability was observed, which was potentially due to the 
variability inherent to experiments which employ cell isolation and ECM-based 
materials, as well as the variability caused by the experimental procedure.  
5.2 Future Work 
5.2.1 Experiments to evaluate applicability of ECM-GelMA-GNR patch to CHD 
treatments 
As this is a preliminary proof of concept study which demonstrated the 
feasibility of tissue regeneration on this ECM-GelMA-GNR hydrogel, further studies 
would be necessary to judge the applicability of this approach to CHD treatments. 
First, physicochemical characterization, including mechanical strength and material 
degradation to assess the capability of the hydrogel patch to withstand surgery 
would be necessary. Second, due to time constrain, other concentrations of GelMA, 
ECM, and GNRs were not explored. Such experiments may be helpful not only in 
terms of determining the optimal composition, but also to understand the underlying 
mechanism of the observations. Third, in vivo study to evaluate the followings would 
be necessary; a) whether host cell would infiltrate into ECM-GelMA-GNR hydrogel, b) 
potential of the hydrogel to transform into a native-like tissue, and c) the growth 
potential of the newly formed tissue. These three points are particularly important to 
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address the unmet need in CHD surgeries; a graft that could integrate with the 
patient’s heart and grow with the patient. 
5.2.2 Experiments to understand the interactions between cells, ECM, GNR, 
and GelMA.  
        It was observed that when three components (ECM, GNR, and GelMA) were 
combined, the spontaneous beating behavior of the cultured cells differed from the 
case of the two-component hydrogel (ECM-GelMA, GelMA-GNR), which is an 
interesting phenomenon. A further investigation utilizing different approaches, such 
as evaluation on gene/protein expression, may give valuable insights to understand 
the underlying mechanism of the phenomenon as well as clues to further improve 
the effectiveness of this ECM-GelMA-GNR hydrogel approach.  
5.2.3 Proteomics on cardiac ECM of CHD patients 
This study was able to achieve the very first step of sample preparation for 
proteomics; generation of peptides from tissues of pediatric patients with CHD. As 
described above, further optimization to increase digestion efficiency would be 
necessary.  
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